Professional
Added to YB: 2025-08-01
Pitch date: 2025-07-28
ADPT [neutral]
Adaptive Biotechnologies Corporation
+45.14%
current return
Author Info
No bio for this author
Company Info
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Market Cap
$2.1B
Pitch Price
$10.81
Price Target
N/A
Dividend
N/A
EV/EBITDA
-46.83
P/E
-25.97
EV/Sales
8.29
Sector
Life Sciences Tools and Services
Category
growth
Aristotle Large Cap Growth Portfolio Holding: Adaptive Biotechnologies Corporation
ADPT (holding update): Q1 earnings exceeded expectations with strong momentum in clinical & biopharma testing volumes. Company improving ASPs, reducing cash burn, and implementing EMR integration to streamline test workflow, increase ordering efficiency, and boost processing/reporting capabilities.
Read full article (1 min)